Articles / New hope for kids with severe food allergies
One of the new class of biologics may have a pivotal role in desensitising children with severe food allergies, US researchers say.
That was the conclusion after their placebo-controlled study showed that a preliminary short course of the monoclonal antibody, omalizumab (Xolair) improved the safety and efficacy of oral immunotherapy in children with multiple severe Ig-E mediated food allergies.
Admittedly the study was small, involving only 48 children aged 4-15 years, and only looked at children with Ig-E mediated allergies to multiple foods but the implications, the study authors say are important.
Lipids Management in GP Demystified
Maintaining Muscles of Independence – Sarcopenia Screening & Management
Work Up of a Breast Lump in GP – Practical Tips and Traps
Managing Opioid Dependence in GP – An Update
Strongly support
Somewhat support
Neither support nor oppose
Somewhat oppose
Strongly oppose
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
You have completed the Educational Activities (EA) component of this activity.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.